Doxycycline Delayed-release Tablets Generics - Manufacturers & Suppliers
Vibramycin (US & EU)
| Product/Composition:- | Doxycycline Delayed-Release Tablets |
|---|---|
| Strength:- | 50 mg, 60 mg, 75 mg, 80 mg, 100 mg, 150 mg, 200 mg.5 Feb 2025 |
| Form:- | Doxycycline Delayed-Release Tablets |
| Reference Brands:- | Vibramycin (US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Doxycycline delayed-release tablets and capsules inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA attachment. They provide sustained, effective antimicrobial action with fewer gastrointestinal side effects, making them suitable for long-term treatment of respiratory, urinary, and skin infections, with benefits including improved compliance and consistent drug levels.
Doxycycline delayed-release tablets and capsules are approved in the EU and US for treating respiratory, urinary, and skin infections. In the EU, brands like Vibramycin XR are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data, with generics widely available. Both regions require detailed dossiers, including clinical trial results, quality assurance, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for doxycycline XR formulations, ensuring adherence to European and US standards for safe, effective antibiotic therapy.